Next-generation CRISPR screens to fast-forward drug discovery

Our technology platform

At Myllia, we perform pooled CRISPR screens and functional genomics at scale in advanced cellular models to map the impact of thousands of genetic perturbations at single-cell resolution – a new paradigm to nominate the best possible targets for your drug discovery campaign. Our functional genomics platform enables tailor-made CRISPR screening:

Circles representing the technology platform for genetic perturbation CRISPR drug screens built at Myllia Biotechnology.

CRISPR screening applications for drug discovery

Pooled CRISPR screens accelerate drug discovery across many therapeutic areas and help unravel gene regulatory networks in cancer cells and primary human T cells. We utilize CRISPR KO, CRISPRi and CRISPRa for genetic perturbation combined with high-throughput functional genomics read-outs. Learn more about CRISPR screening for various applications:

Target icon symbolising crispr screen target identification and validation

Drug target identification and validation, incl. target deconvolution

Screen in blue with an ascending graph representing the CRISPR screen analysis.

Mode of action (MoA) analysis and drug signature CRISPR screening

DNA icon in blue to illustrate the identification of disease-associated gene functions.

Identification of disease-associated gene function using functional genomics

Network icon in blue to illustrate the genetic perturbation screening of primary T cell subsets.

Genetic perturbation screening for immune pathways and primary T cell phenotypes

Genetic perturbation screens and functional genomics at single-cell resolution revolutionize the way we identify novel drug targets and gene regulatory networks involved in oncology and autoimmune disease.